8th European Breast Cancer Conference, Vienna 2012

摘要

The 8th European Breast Cancer Conference took place in Austria Center Vienna from 21-24 March 2012. Neoadjuvant therapy is increasingly being used as a method of assessing new drugs and shrinking tumors to allow breast-conserving surgery, thus avoiding mastectomy and improving cosmetic outcomes. Long-term follow-up data from NSABP B18 shows improved survival from 5-15 years after neo-adjuvant chemotherapy (NAC) with a borderline significant improvement in overall survival (OS) in favor of NAC in younger but not older women, One issue is the poor response of ductal carcinoma in situ to chemotherapy, which can mean that mastectomy is still inevitable in some patients with invasive cancer with extensive ductal carcinoma in situ (DCIS), even if the invasive disease responds